Generating AI analysis...
Revenue
$62.58B
-1.65% YoY
EPS (Basic)
$1.37
-3.52% YoY
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $62.58B | $63.63B | -1.65% |
Cost of Revenue | $16.07B | $17.85B | -9.99% |
Net Income | $7.77B | $8.03B | -3.24% |
EPS (Basic) | $1.37 | $1.42 | -3.52% |
EPS (Diluted) | $1.36 | $1.41 | -3.55% |
SG&A Expense | $13.79B | $14.73B | -6.35% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $208.16B | $213.4B | -2.45% |
Current Assets | $42.9B | $50.36B | -14.81% |
Total Liabilities | $121.39B | $124.9B | -2.81% |
Current Liabilities | $36.98B | $42.99B | -13.98% |
Stockholders' Equity | $86.48B | $88.2B | -1.96% |
Cash & Equivalents | $1.14B | $1.04B | +9.49% |
Long-Term Debt | $61.64B | $57.41B | +7.38% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $11.7B | $12.74B | -8.16% |
Investing Cash Flow | $-1.35B | $2.65B | -150.94% |
Financing Cash Flow | $-10.3B | $-17.14B | +39.88% |
D&A | $6.59B | $7.01B | -6.00% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | 12.4% | — | — |
ROE | 9.0% | — | — |
ROA | 3.7% | — | — |
Current Ratio | $1.16 | — | — |
Debt to Equity | $1.404 | — | — |
Other companies in Pharmaceuticals